nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR1D—meninx—malignant glioma	0.0754	0.109	CbGeAlD
Methysergide—HTR1B—dura mater—malignant glioma	0.0717	0.103	CbGeAlD
Methysergide—HTR1D—dura mater—malignant glioma	0.0694	0.1	CbGeAlD
Methysergide—HTR2C—choroid plexus—malignant glioma	0.0584	0.0843	CbGeAlD
Methysergide—HTR2A—choroid plexus—malignant glioma	0.0293	0.0423	CbGeAlD
Methysergide—Leg edema—Temozolomide—malignant glioma	0.0202	0.118	CcSEcCtD
Methysergide—HTR1B—telencephalic ventricle—malignant glioma	0.0179	0.0257	CbGeAlD
Methysergide—HTR1D—telencephalic ventricle—malignant glioma	0.0173	0.0249	CbGeAlD
Methysergide—HTR2C—telencephalic ventricle—malignant glioma	0.0171	0.0247	CbGeAlD
Methysergide—HTR7—pons—malignant glioma	0.0167	0.0241	CbGeAlD
Methysergide—HTR2A—cerebellar cortex—malignant glioma	0.0148	0.0213	CbGeAlD
Methysergide—HTR1A—telencephalic ventricle—malignant glioma	0.0144	0.0208	CbGeAlD
Methysergide—HTR7—telencephalic ventricle—malignant glioma	0.0138	0.0199	CbGeAlD
Methysergide—HTR1F—telencephalon—malignant glioma	0.0105	0.0151	CbGeAlD
Methysergide—HTR2A—pons—malignant glioma	0.0104	0.015	CbGeAlD
Methysergide—HTR2A—vertebral column—malignant glioma	0.0104	0.0149	CbGeAlD
Methysergide—HTR1E—brainstem—malignant glioma	0.0102	0.0147	CbGeAlD
Methysergide—HTR1E—telencephalon—malignant glioma	0.00906	0.0131	CbGeAlD
Methysergide—HTR1B—blood vessel—malignant glioma	0.00884	0.0127	CbGeAlD
Methysergide—HTR2A—telencephalic ventricle—malignant glioma	0.00859	0.0124	CbGeAlD
Methysergide—HTR1D—blood vessel—malignant glioma	0.00856	0.0123	CbGeAlD
Methysergide—HTR2A—pineal body—malignant glioma	0.00745	0.0107	CbGeAlD
Methysergide—HTR7—endothelium—malignant glioma	0.00739	0.0107	CbGeAlD
Methysergide—HTR6—telencephalon—malignant glioma	0.00711	0.0103	CbGeAlD
Methysergide—Hyperaesthesia—Temozolomide—malignant glioma	0.00691	0.0406	CcSEcCtD
Methysergide—HTR7—blood vessel—malignant glioma	0.00682	0.00983	CbGeAlD
Methysergide—HTR1F—central nervous system—malignant glioma	0.00595	0.00858	CbGeAlD
Methysergide—HTR1E—central nervous system—malignant glioma	0.00515	0.00743	CbGeAlD
Methysergide—HTR1B—brainstem—malignant glioma	0.00483	0.00697	CbGeAlD
Methysergide—HTR1F—brain—malignant glioma	0.00472	0.00681	CbGeAlD
Methysergide—Thrombophlebitis—Carmustine—malignant glioma	0.00471	0.0277	CcSEcCtD
Methysergide—HTR1D—brainstem—malignant glioma	0.00468	0.00675	CbGeAlD
Methysergide—HTR2C—brainstem—malignant glioma	0.00463	0.00668	CbGeAlD
Methysergide—HTR2A—endothelium—malignant glioma	0.00461	0.00665	CbGeAlD
Methysergide—Thrombophlebitis—Temozolomide—malignant glioma	0.00455	0.0267	CcSEcCtD
Methysergide—HTR1B—telencephalon—malignant glioma	0.00429	0.00618	CbGeAlD
Methysergide—HTR2A—blood vessel—malignant glioma	0.00425	0.00613	CbGeAlD
Methysergide—HTR1D—telencephalon—malignant glioma	0.00415	0.00599	CbGeAlD
Methysergide—HTR2C—telencephalon—malignant glioma	0.00411	0.00593	CbGeAlD
Methysergide—HTR1E—brain—malignant glioma	0.00409	0.0059	CbGeAlD
Methysergide—HTR6—central nervous system—malignant glioma	0.00404	0.00583	CbGeAlD
Methysergide—HTR1A—brainstem—malignant glioma	0.0039	0.00562	CbGeAlD
Methysergide—SIGMAR1—telencephalon—malignant glioma	0.00387	0.00558	CbGeAlD
Methysergide—HTR2B—telencephalon—malignant glioma	0.00386	0.00557	CbGeAlD
Methysergide—Ataxia—Carmustine—malignant glioma	0.00383	0.0225	CcSEcCtD
Methysergide—HTR7—brainstem—malignant glioma	0.00373	0.00537	CbGeAlD
Methysergide—Ataxia—Temozolomide—malignant glioma	0.0037	0.0218	CcSEcCtD
Methysergide—HTR1A—telencephalon—malignant glioma	0.00346	0.00499	CbGeAlD
Methysergide—HTR7—telencephalon—malignant glioma	0.00331	0.00477	CbGeAlD
Methysergide—Neutropenia—Carmustine—malignant glioma	0.00329	0.0194	CcSEcCtD
Methysergide—HTR2C—medulla oblongata—malignant glioma	0.00323	0.00466	CbGeAlD
Methysergide—HTR6—brain—malignant glioma	0.00321	0.00463	CbGeAlD
Methysergide—Neutropenia—Temozolomide—malignant glioma	0.00318	0.0187	CcSEcCtD
Methysergide—Dysuria—Temozolomide—malignant glioma	0.00318	0.0187	CcSEcCtD
Methysergide—Weight increased—Temozolomide—malignant glioma	0.0031	0.0182	CcSEcCtD
Methysergide—Weight decreased—Temozolomide—malignant glioma	0.00308	0.0181	CcSEcCtD
Methysergide—HTR1B—midbrain—malignant glioma	0.00308	0.00444	CbGeAlD
Methysergide—SIGMAR1—medulla oblongata—malignant glioma	0.00304	0.00439	CbGeAlD
Methysergide—HTR1B—spinal cord—malignant glioma	0.003	0.00433	CbGeAlD
Methysergide—HTR1D—midbrain—malignant glioma	0.00298	0.0043	CbGeAlD
Methysergide—HTR2C—midbrain—malignant glioma	0.00295	0.00426	CbGeAlD
Methysergide—HTR2C—spinal cord—malignant glioma	0.00288	0.00415	CbGeAlD
Methysergide—SIGMAR1—midbrain—malignant glioma	0.00278	0.00401	CbGeAlD
Methysergide—Oedema peripheral—Carmustine—malignant glioma	0.00278	0.0163	CcSEcCtD
Methysergide—SIGMAR1—spinal cord—malignant glioma	0.00271	0.00391	CbGeAlD
Methysergide—Oedema peripheral—Temozolomide—malignant glioma	0.00268	0.0158	CcSEcCtD
Methysergide—Flushing—Carmustine—malignant glioma	0.00262	0.0154	CcSEcCtD
Methysergide—HTR7—medulla oblongata—malignant glioma	0.0026	0.00375	CbGeAlD
Methysergide—HTR2A—embryo—malignant glioma	0.00254	0.00366	CbGeAlD
Methysergide—Flushing—Temozolomide—malignant glioma	0.00253	0.0149	CcSEcCtD
Methysergide—Alopecia—Carmustine—malignant glioma	0.00249	0.0146	CcSEcCtD
Methysergide—HTR1A—midbrain—malignant glioma	0.00248	0.00358	CbGeAlD
Methysergide—HTR1B—central nervous system—malignant glioma	0.00244	0.00351	CbGeAlD
Methysergide—HTR1A—spinal cord—malignant glioma	0.00242	0.0035	CbGeAlD
Methysergide—Alopecia—Temozolomide—malignant glioma	0.00241	0.0141	CcSEcCtD
Methysergide—Back pain—Carmustine—malignant glioma	0.00237	0.0139	CcSEcCtD
Methysergide—HTR7—midbrain—malignant glioma	0.00237	0.00342	CbGeAlD
Methysergide—HTR1D—central nervous system—malignant glioma	0.00236	0.0034	CbGeAlD
Methysergide—HTR2C—central nervous system—malignant glioma	0.00234	0.00337	CbGeAlD
Methysergide—HTR2A—brainstem—malignant glioma	0.00232	0.00335	CbGeAlD
Methysergide—HTR7—spinal cord—malignant glioma	0.00232	0.00334	CbGeAlD
Methysergide—Back pain—Temozolomide—malignant glioma	0.00229	0.0135	CcSEcCtD
Methysergide—HTR2A—retina—malignant glioma	0.00224	0.00323	CbGeAlD
Methysergide—Ill-defined disorder—Temozolomide—malignant glioma	0.0022	0.0129	CcSEcCtD
Methysergide—HTR2B—central nervous system—malignant glioma	0.00219	0.00317	CbGeAlD
Methysergide—SIGMAR1—cerebellum—malignant glioma	0.00215	0.0031	CbGeAlD
Methysergide—Malaise—Temozolomide—malignant glioma	0.00214	0.0126	CcSEcCtD
Methysergide—Convulsion—Carmustine—malignant glioma	0.00213	0.0125	CcSEcCtD
Methysergide—Chest pain—Carmustine—malignant glioma	0.00209	0.0123	CcSEcCtD
Methysergide—Myalgia—Carmustine—malignant glioma	0.00209	0.0123	CcSEcCtD
Methysergide—HTR2A—telencephalon—malignant glioma	0.00206	0.00297	CbGeAlD
Methysergide—Convulsion—Temozolomide—malignant glioma	0.00206	0.0121	CcSEcCtD
Methysergide—Myalgia—Temozolomide—malignant glioma	0.00202	0.0119	CcSEcCtD
Methysergide—Arthralgia—Temozolomide—malignant glioma	0.00202	0.0119	CcSEcCtD
Methysergide—Oedema—Carmustine—malignant glioma	0.002	0.0118	CcSEcCtD
Methysergide—Discomfort—Temozolomide—malignant glioma	0.002	0.0117	CcSEcCtD
Methysergide—HTR1A—central nervous system—malignant glioma	0.00197	0.00284	CbGeAlD
Methysergide—Thrombocytopenia—Carmustine—malignant glioma	0.00196	0.0115	CcSEcCtD
Methysergide—Tachycardia—Carmustine—malignant glioma	0.00196	0.0115	CcSEcCtD
Methysergide—Oedema—Temozolomide—malignant glioma	0.00194	0.0114	CcSEcCtD
Methysergide—HTR1B—brain—malignant glioma	0.00193	0.00279	CbGeAlD
Methysergide—HTR1A—cerebellum—malignant glioma	0.00192	0.00277	CbGeAlD
Methysergide—Thrombocytopenia—Temozolomide—malignant glioma	0.0019	0.0111	CcSEcCtD
Methysergide—HTR7—central nervous system—malignant glioma	0.00188	0.00271	CbGeAlD
Methysergide—HTR1D—brain—malignant glioma	0.00187	0.0027	CbGeAlD
Methysergide—HTR2C—brain—malignant glioma	0.00185	0.00267	CbGeAlD
Methysergide—HTR7—cerebellum—malignant glioma	0.00184	0.00265	CbGeAlD
Methysergide—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00183	0.0107	CcSEcCtD
Methysergide—Insomnia—Carmustine—malignant glioma	0.00181	0.0106	CcSEcCtD
Methysergide—Paraesthesia—Carmustine—malignant glioma	0.0018	0.0106	CcSEcCtD
Methysergide—Dyspnoea—Carmustine—malignant glioma	0.00179	0.0105	CcSEcCtD
Methysergide—Somnolence—Carmustine—malignant glioma	0.00178	0.0105	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00176	0.0104	CcSEcCtD
Methysergide—Insomnia—Temozolomide—malignant glioma	0.00175	0.0103	CcSEcCtD
Methysergide—SIGMAR1—brain—malignant glioma	0.00175	0.00252	CbGeAlD
Methysergide—HTR2B—brain—malignant glioma	0.00174	0.00251	CbGeAlD
Methysergide—Paraesthesia—Temozolomide—malignant glioma	0.00174	0.0102	CcSEcCtD
Methysergide—Gastrointestinal disorder—Carmustine—malignant glioma	0.00173	0.0102	CcSEcCtD
Methysergide—Dyspnoea—Temozolomide—malignant glioma	0.00173	0.0101	CcSEcCtD
Methysergide—Somnolence—Temozolomide—malignant glioma	0.00172	0.0101	CcSEcCtD
Methysergide—Pain—Carmustine—malignant glioma	0.00171	0.0101	CcSEcCtD
Methysergide—Constipation—Carmustine—malignant glioma	0.00171	0.0101	CcSEcCtD
Methysergide—Dyspepsia—Temozolomide—malignant glioma	0.0017	0.01	CcSEcCtD
Methysergide—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00167	0.00982	CcSEcCtD
Methysergide—Fatigue—Temozolomide—malignant glioma	0.00167	0.00981	CcSEcCtD
Methysergide—Constipation—Temozolomide—malignant glioma	0.00166	0.00973	CcSEcCtD
Methysergide—Pain—Temozolomide—malignant glioma	0.00166	0.00973	CcSEcCtD
Methysergide—Feeling abnormal—Carmustine—malignant glioma	0.00165	0.0097	CcSEcCtD
Methysergide—Gastrointestinal pain—Carmustine—malignant glioma	0.00164	0.00962	CcSEcCtD
Methysergide—HTR2A—medulla oblongata—malignant glioma	0.00162	0.00234	CbGeAlD
Methysergide—Feeling abnormal—Temozolomide—malignant glioma	0.0016	0.00937	CcSEcCtD
Methysergide—Body temperature increased—Carmustine—malignant glioma	0.00158	0.0093	CcSEcCtD
Methysergide—Abdominal pain—Carmustine—malignant glioma	0.00158	0.0093	CcSEcCtD
Methysergide—Gastrointestinal pain—Temozolomide—malignant glioma	0.00158	0.0093	CcSEcCtD
Methysergide—HTR1A—brain—malignant glioma	0.00156	0.00225	CbGeAlD
Methysergide—Body temperature increased—Temozolomide—malignant glioma	0.00153	0.00899	CcSEcCtD
Methysergide—Abdominal pain—Temozolomide—malignant glioma	0.00153	0.00899	CcSEcCtD
Methysergide—HTR7—brain—malignant glioma	0.00149	0.00215	CbGeAlD
Methysergide—HTR2A—midbrain—malignant glioma	0.00148	0.00214	CbGeAlD
Methysergide—HTR2A—spinal cord—malignant glioma	0.00144	0.00208	CbGeAlD
Methysergide—Asthenia—Carmustine—malignant glioma	0.00144	0.00844	CcSEcCtD
Methysergide—Asthenia—Temozolomide—malignant glioma	0.00139	0.00816	CcSEcCtD
Methysergide—Diarrhoea—Carmustine—malignant glioma	0.00137	0.00805	CcSEcCtD
Methysergide—Dizziness—Carmustine—malignant glioma	0.00132	0.00778	CcSEcCtD
Methysergide—Diarrhoea—Temozolomide—malignant glioma	0.00132	0.00778	CcSEcCtD
Methysergide—Dizziness—Temozolomide—malignant glioma	0.00128	0.00752	CcSEcCtD
Methysergide—Vomiting—Carmustine—malignant glioma	0.00127	0.00748	CcSEcCtD
Methysergide—Rash—Carmustine—malignant glioma	0.00126	0.00742	CcSEcCtD
Methysergide—Dermatitis—Carmustine—malignant glioma	0.00126	0.00741	CcSEcCtD
Methysergide—Vomiting—Temozolomide—malignant glioma	0.00123	0.00723	CcSEcCtD
Methysergide—Rash—Temozolomide—malignant glioma	0.00122	0.00717	CcSEcCtD
Methysergide—Dermatitis—Temozolomide—malignant glioma	0.00122	0.00716	CcSEcCtD
Methysergide—Nausea—Carmustine—malignant glioma	0.00119	0.00699	CcSEcCtD
Methysergide—HTR2A—central nervous system—malignant glioma	0.00117	0.00169	CbGeAlD
Methysergide—Nausea—Temozolomide—malignant glioma	0.00115	0.00676	CcSEcCtD
Methysergide—HTR2A—cerebellum—malignant glioma	0.00115	0.00165	CbGeAlD
Methysergide—HTR2A—brain—malignant glioma	0.00093	0.00134	CbGeAlD
Methysergide—HTR2C—Signaling Pathways—FGFR1—malignant glioma	3.07e-05	0.000225	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—PIK3CA—malignant glioma	3.06e-05	0.000224	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—FGF2—malignant glioma	3.04e-05	0.000223	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—FGF2—malignant glioma	3.04e-05	0.000223	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HIF1A—malignant glioma	3.03e-05	0.000223	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—IL2—malignant glioma	3.03e-05	0.000222	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—KRAS—malignant glioma	3.02e-05	0.000222	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HIF1A—malignant glioma	3.02e-05	0.000221	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—FGF2—malignant glioma	3.02e-05	0.000221	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—EGFR—malignant glioma	3.02e-05	0.000221	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT2—malignant glioma	3.02e-05	0.000221	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—EGFR—malignant glioma	3e-05	0.00022	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3CB—malignant glioma	3e-05	0.00022	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PDGFRA—malignant glioma	2.98e-05	0.000218	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—FGF2—malignant glioma	2.95e-05	0.000217	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CAV1—malignant glioma	2.93e-05	0.000215	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CAV1—malignant glioma	2.92e-05	0.000214	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MYC—malignant glioma	2.91e-05	0.000213	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KDR—malignant glioma	2.9e-05	0.000213	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CD—malignant glioma	2.9e-05	0.000213	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SPP1—malignant glioma	2.89e-05	0.000212	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KDR—malignant glioma	2.89e-05	0.000212	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CXCL8—malignant glioma	2.88e-05	0.000211	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—PIK3CA—malignant glioma	2.87e-05	0.000211	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—PIK3CA—malignant glioma	2.86e-05	0.000209	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—PIK3CA—malignant glioma	2.85e-05	0.000209	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—KRAS—malignant glioma	2.85e-05	0.000209	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—EGFR—malignant glioma	2.85e-05	0.000209	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MDM2—malignant glioma	2.84e-05	0.000209	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MDM2—malignant glioma	2.84e-05	0.000208	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—KRAS—malignant glioma	2.84e-05	0.000208	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—RAF1—malignant glioma	2.83e-05	0.000208	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—PIK3CA—malignant glioma	2.83e-05	0.000208	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—RAF1—malignant glioma	2.83e-05	0.000208	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MDM2—malignant glioma	2.82e-05	0.000207	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—RAF1—malignant glioma	2.81e-05	0.000206	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—ERBB2—malignant glioma	2.8e-05	0.000206	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—ERBB2—malignant glioma	2.8e-05	0.000205	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—F2—malignant glioma	2.79e-05	0.000205	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—FN1—malignant glioma	2.79e-05	0.000205	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—ERBB2—malignant glioma	2.78e-05	0.000204	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—F2—malignant glioma	2.78e-05	0.000204	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—FN1—malignant glioma	2.78e-05	0.000204	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—PIK3CA—malignant glioma	2.77e-05	0.000204	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—FGF2—malignant glioma	2.77e-05	0.000204	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CB—malignant glioma	2.77e-05	0.000203	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CB—malignant glioma	2.76e-05	0.000203	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MDM2—malignant glioma	2.76e-05	0.000203	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—BAD—malignant glioma	2.76e-05	0.000202	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—RAF1—malignant glioma	2.75e-05	0.000202	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL2—malignant glioma	2.75e-05	0.000202	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CB—malignant glioma	2.75e-05	0.000201	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—BAD—malignant glioma	2.75e-05	0.000201	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TERT—malignant glioma	2.74e-05	0.000201	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NOTCH1—malignant glioma	2.73e-05	0.000201	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—ERBB2—malignant glioma	2.72e-05	0.0002	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NOTCH1—malignant glioma	2.72e-05	0.000199	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CB—malignant glioma	2.69e-05	0.000197	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—KRAS—malignant glioma	2.69e-05	0.000197	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CD80—malignant glioma	2.68e-05	0.000196	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PDGFB—malignant glioma	2.68e-05	0.000196	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CG—malignant glioma	2.67e-05	0.000196	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—APC—malignant glioma	2.67e-05	0.000196	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CD80—malignant glioma	2.66e-05	0.000195	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FGFR1—malignant glioma	2.66e-05	0.000195	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CG—malignant glioma	2.66e-05	0.000195	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—APC—malignant glioma	2.66e-05	0.000195	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CXCL8—malignant glioma	2.66e-05	0.000195	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CXCL8—malignant glioma	2.66e-05	0.000195	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGF—malignant glioma	2.64e-05	0.000194	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CXCL8—malignant glioma	2.64e-05	0.000194	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGF—malignant glioma	2.63e-05	0.000193	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTPN11—malignant glioma	2.63e-05	0.000193	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HIF1A—malignant glioma	2.62e-05	0.000192	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—PIK3CA—malignant glioma	2.62e-05	0.000192	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTPN11—malignant glioma	2.61e-05	0.000192	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—PIK3CA—malignant glioma	2.61e-05	0.000191	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MDM2—malignant glioma	2.6e-05	0.00019	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—RAF1—malignant glioma	2.59e-05	0.00019	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CXCL8—malignant glioma	2.58e-05	0.00019	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—AKT1—malignant glioma	2.57e-05	0.000188	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—AKT1—malignant glioma	2.57e-05	0.000188	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—ERBB2—malignant glioma	2.56e-05	0.000188	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—AKT1—malignant glioma	2.55e-05	0.000187	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CASP3—malignant glioma	2.55e-05	0.000187	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CASP3—malignant glioma	2.54e-05	0.000186	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL2—malignant glioma	2.54e-05	0.000186	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL2—malignant glioma	2.54e-05	0.000186	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CAV1—malignant glioma	2.54e-05	0.000186	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TP53—malignant glioma	2.53e-05	0.000186	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CB—malignant glioma	2.53e-05	0.000185	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CASP3—malignant glioma	2.53e-05	0.000185	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL2—malignant glioma	2.52e-05	0.000185	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—BRAF—malignant glioma	2.51e-05	0.000184	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KDR—malignant glioma	2.51e-05	0.000184	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—BRAF—malignant glioma	2.5e-05	0.000183	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKT1—malignant glioma	2.5e-05	0.000183	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CASP3—malignant glioma	2.47e-05	0.000181	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL2—malignant glioma	2.47e-05	0.000181	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PIK3CA—malignant glioma	2.47e-05	0.000181	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT2—malignant glioma	2.45e-05	0.000179	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—EGFR—malignant glioma	2.44e-05	0.000179	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT2—malignant glioma	2.43e-05	0.000178	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CXCL8—malignant glioma	2.43e-05	0.000178	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—EGFR—malignant glioma	2.42e-05	0.000178	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—F2—malignant glioma	2.41e-05	0.000177	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FN1—malignant glioma	2.41e-05	0.000177	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MMP9—malignant glioma	2.41e-05	0.000176	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MMP9—malignant glioma	2.4e-05	0.000176	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTEN—malignant glioma	2.39e-05	0.000175	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—malignant glioma	2.39e-05	0.000175	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTEN—malignant glioma	2.39e-05	0.000175	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MMP9—malignant glioma	2.39e-05	0.000175	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BAD—malignant glioma	2.38e-05	0.000175	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTEN—malignant glioma	2.37e-05	0.000174	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOTCH1—malignant glioma	2.36e-05	0.000173	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CD—malignant glioma	2.35e-05	0.000172	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—malignant glioma	2.34e-05	0.000172	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CD—malignant glioma	2.34e-05	0.000171	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MMP9—malignant glioma	2.34e-05	0.000171	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—malignant glioma	2.33e-05	0.000171	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—malignant glioma	2.33e-05	0.000171	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—PIK3CA—malignant glioma	2.33e-05	0.000171	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTEN—malignant glioma	2.32e-05	0.00017	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CASP3—malignant glioma	2.32e-05	0.00017	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL2—malignant glioma	2.32e-05	0.00017	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—PIK3CA—malignant glioma	2.32e-05	0.00017	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—malignant glioma	2.32e-05	0.00017	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CD80—malignant glioma	2.31e-05	0.00017	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APC—malignant glioma	2.31e-05	0.000169	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CG—malignant glioma	2.31e-05	0.000169	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—KRAS—malignant glioma	2.3e-05	0.000169	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—KRAS—malignant glioma	2.29e-05	0.000168	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGF—malignant glioma	2.28e-05	0.000167	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTPN11—malignant glioma	2.27e-05	0.000166	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—malignant glioma	2.27e-05	0.000166	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—FGF2—malignant glioma	2.25e-05	0.000165	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—FGF2—malignant glioma	2.24e-05	0.000164	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MMP9—malignant glioma	2.2e-05	0.000161	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTEN—malignant glioma	2.18e-05	0.00016	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BRAF—malignant glioma	2.17e-05	0.000159	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—VEGFA—malignant glioma	2.16e-05	0.000158	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—VEGFA—malignant glioma	2.16e-05	0.000158	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—VEGFA—malignant glioma	2.14e-05	0.000157	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—malignant glioma	2.14e-05	0.000157	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—malignant glioma	2.14e-05	0.000157	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—malignant glioma	2.14e-05	0.000157	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—malignant glioma	2.13e-05	0.000156	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—malignant glioma	2.12e-05	0.000156	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PIK3CA—malignant glioma	2.11e-05	0.000155	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT2—malignant glioma	2.11e-05	0.000155	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MDM2—malignant glioma	2.11e-05	0.000154	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—EGFR—malignant glioma	2.1e-05	0.000154	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	2.1e-05	0.000154	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—VEGFA—malignant glioma	2.1e-05	0.000154	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—RAF1—malignant glioma	2.1e-05	0.000154	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MDM2—malignant glioma	2.09e-05	0.000154	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—RAF1—malignant glioma	2.09e-05	0.000153	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—malignant glioma	2.08e-05	0.000152	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—ERBB2—malignant glioma	2.08e-05	0.000152	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—ERBB2—malignant glioma	2.07e-05	0.000151	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CB—malignant glioma	2.05e-05	0.00015	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	2.04e-05	0.000149	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	2.03e-05	0.000149	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—malignant glioma	2.02e-05	0.000148	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	2.01e-05	0.000147	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—KRAS—malignant glioma	1.99e-05	0.000146	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MYC—malignant glioma	1.99e-05	0.000146	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MYC—malignant glioma	1.99e-05	0.000146	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MYC—malignant glioma	1.97e-05	0.000145	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—VEGFA—malignant glioma	1.97e-05	0.000145	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CXCL8—malignant glioma	1.97e-05	0.000144	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CXCL8—malignant glioma	1.96e-05	0.000144	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—malignant glioma	1.95e-05	0.000143	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FGF2—malignant glioma	1.94e-05	0.000143	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EGFR—malignant glioma	1.94e-05	0.000143	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EGFR—malignant glioma	1.94e-05	0.000142	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MYC—malignant glioma	1.93e-05	0.000142	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EGFR—malignant glioma	1.93e-05	0.000141	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—malignant glioma	1.9e-05	0.000139	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	1.89e-05	0.000139	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EGFR—malignant glioma	1.89e-05	0.000139	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CASP3—malignant glioma	1.88e-05	0.000138	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL2—malignant glioma	1.88e-05	0.000138	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CASP3—malignant glioma	1.87e-05	0.000137	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL2—malignant glioma	1.87e-05	0.000137	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KRAS—malignant glioma	1.84e-05	0.000135	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KRAS—malignant glioma	1.83e-05	0.000135	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	1.83e-05	0.000134	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KRAS—malignant glioma	1.82e-05	0.000134	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MDM2—malignant glioma	1.82e-05	0.000133	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MYC—malignant glioma	1.81e-05	0.000133	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—RAF1—malignant glioma	1.81e-05	0.000133	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ERBB2—malignant glioma	1.79e-05	0.000132	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KRAS—malignant glioma	1.78e-05	0.000131	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MMP9—malignant glioma	1.78e-05	0.000131	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EGFR—malignant glioma	1.77e-05	0.00013	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MMP9—malignant glioma	1.77e-05	0.00013	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTEN—malignant glioma	1.77e-05	0.00013	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	1.77e-05	0.00013	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTEN—malignant glioma	1.76e-05	0.000129	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—malignant glioma	1.73e-05	0.000127	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—malignant glioma	1.72e-05	0.000126	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CXCL8—malignant glioma	1.7e-05	0.000125	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CA—malignant glioma	1.69e-05	0.000124	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CA—malignant glioma	1.69e-05	0.000124	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KRAS—malignant glioma	1.68e-05	0.000123	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CA—malignant glioma	1.67e-05	0.000123	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	1.64e-05	0.00012	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CA—malignant glioma	1.64e-05	0.00012	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—malignant glioma	1.63e-05	0.00012	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—malignant glioma	1.63e-05	0.00012	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CASP3—malignant glioma	1.63e-05	0.000119	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL2—malignant glioma	1.63e-05	0.000119	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—malignant glioma	1.62e-05	0.000119	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—VEGFA—malignant glioma	1.6e-05	0.000117	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—VEGFA—malignant glioma	1.59e-05	0.000117	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—malignant glioma	1.59e-05	0.000116	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—malignant glioma	1.58e-05	0.000116	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—malignant glioma	1.57e-05	0.000116	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CA—malignant glioma	1.54e-05	0.000113	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP9—malignant glioma	1.54e-05	0.000113	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTEN—malignant glioma	1.53e-05	0.000112	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—malignant glioma	1.49e-05	0.000109	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—malignant glioma	1.49e-05	0.000109	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MYC—malignant glioma	1.47e-05	0.000108	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MYC—malignant glioma	1.46e-05	0.000107	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGFR—malignant glioma	1.44e-05	0.000106	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGFR—malignant glioma	1.43e-05	0.000105	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—VEGFA—malignant glioma	1.38e-05	0.000101	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—malignant glioma	1.38e-05	0.000101	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—malignant glioma	1.38e-05	0.000101	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—malignant glioma	1.37e-05	0.0001	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—malignant glioma	1.37e-05	0.0001	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KRAS—malignant glioma	1.36e-05	9.97e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KRAS—malignant glioma	1.35e-05	9.92e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—malignant glioma	1.34e-05	9.82e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MYC—malignant glioma	1.27e-05	9.32e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—malignant glioma	1.26e-05	9.23e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	1.25e-05	9.16e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGFR—malignant glioma	1.24e-05	9.12e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	1.24e-05	9.11e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—malignant glioma	1.21e-05	8.86e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—malignant glioma	1.2e-05	8.81e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KRAS—malignant glioma	1.17e-05	8.61e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	1.08e-05	7.91e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—malignant glioma	1.04e-05	7.65e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—malignant glioma	1.02e-05	7.48e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—malignant glioma	1.01e-05	7.44e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—malignant glioma	8.81e-06	6.46e-05	CbGpPWpGaD
